FDA approves weight loss drug Zepbound to treat obstructive sleep apnea

Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. Studies show Zepbound, used with a reduced-calorie diet and exercise, significantly reduces OSA symptoms. The American Academy of Sleep Medicine supports its use but notes it's not for everyone, emphasizing sustained weight loss is crucial for its effectiveness.